Om

Vicore Pharma Holding AB Sponsored ADR is a clinical-stage biopharmaceutical asset focused on developing treatments for respiratory and fibrotic diseases, with an emphasis on idiopathic pulmonary fibrosis and related interstitial lung conditions. The company’s current portfolio centers on buloxibutid, an oral small-molecule angiotensin II type 2 receptor agonist being evaluated in late-stage clinical development, alongside additional programs aimed at rare lung disorders and disease-related symptoms. Vicore Pharma also works on supportive digital and device-based solutions designed to address the broader impact of chronic pulmonary disease. Based in Stockholm, Sweden, the company operates as a research-driven drug developer whose role in the market is to advance innovative therapies from discovery into clinical validation for high-unmet-need respiratory indications.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VICORE PHARMA HOLDING - ADR MED ENDAVU: Køb Vicore Pharma Holding - ADR ($VCRE) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Vicore Pharma Holding - ADR, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.